MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

AnaptysBio Inc

Fermé

SecteurSoins de santé

25.84 -2.67

Résumé

Variation du prix de l'action

24h

Actuel

Min

25.73

Max

26.79

Chiffres clés

By Trading Economics

Revenu

-18M

-39M

Ventes

-15M

28M

Marge bénéficiaire

-141.619

Employés

136

EBITDA

-24M

-28M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+90.63% upside

Dividendes

By Dow Jones

Prochains Résultats

1 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

179M

792M

Ouverture précédente

28.51

Clôture précédente

25.84

Sentiment de l'Actualité

By Acuity

67%

33%

328 / 376 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

AnaptysBio Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 juil. 2025, 21:01 UTC

Résultats

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 juil. 2025, 20:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

18 juil. 2025, 20:50 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

18 juil. 2025, 20:50 UTC

Market Talk
Résultats

Basic Materials Roundup: Market Talk

18 juil. 2025, 20:46 UTC

Résultats

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 juil. 2025, 20:39 UTC

Acquisitions, Fusions, Rachats

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 juil. 2025, 20:36 UTC

Résultats

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 juil. 2025, 20:16 UTC

Acquisitions, Fusions, Rachats

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 juil. 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 juil. 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18 juil. 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 juil. 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 juil. 2025, 18:24 UTC

Résultats

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 juil. 2025, 18:19 UTC

Résultats

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 juil. 2025, 18:11 UTC

Acquisitions, Fusions, Rachats

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 juil. 2025, 18:11 UTC

Résultats

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 juil. 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 juil. 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 juil. 2025, 16:28 UTC

Acquisitions, Fusions, Rachats

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 juil. 2025, 16:22 UTC

Résultats

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 juil. 2025, 16:20 UTC

Market Talk
Résultats

Financial Services Roundup: Market Talk

18 juil. 2025, 16:20 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

18 juil. 2025, 16:20 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

18 juil. 2025, 16:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Energy & Utilities Roundup: Market Talk

18 juil. 2025, 16:20 UTC

Market Talk
Résultats

Basic Materials Roundup: Market Talk

18 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 juil. 2025, 16:04 UTC

Résultats

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 juil. 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18 juil. 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 juil. 2025, 15:47 UTC

Market Talk
Résultats

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Comparaison

Variation de prix

AnaptysBio Inc prévision

Objectif de Prix

By TipRanks

90.63% hausse

Prévisions sur 12 Mois

Moyen 50.86 USD  90.63%

Haut 90 USD

Bas 25 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

11 ratings

10

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

19.25 / 21.135Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Neutral Evidence

Sentiment

By Acuity

328 / 376Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.